We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Novartis AG | NYSE:NVS | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -1.37 | -1.45% | 93.04 | 5,530 | 12:37:43 |
From Apr 2022 to Apr 2024
By Pierre Bertrand
Novartis AG said Thursday that a Phase 3 trial for its drug iptacopan has met its primary endpoint of boosting hemoglobin levels.
The Swiss pharma company said the trial showed that patients treated twice daily with the drug achieved clinically meaningful hemoglobin-level increases without the need for blood transfusions at 24 weeks.
Iptacopan is a treatment for blood disease paroxysmal nocturnal hemoglobinuria, which causes the premature death of red blood cells. Patients with PNH suffer anemia, fatigue and require blood transfusions.
Write to Pierre Bertrand at pierre.bertrand@wsj.com
(END) Dow Jones Newswires
December 08, 2022 01:57 ET (06:57 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Novartis Chart |
1 Month Novartis Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
